Alnylam Pharmaceuticals
ALNY
#378
Rank
โ‚น5.437 T
Marketcap
โ‚น41,156
Share price
-1.55%
Change (1 day)
89.69%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2025 (TTM): โ‚น12.04 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are โ‚น3.21 Billion. In 2024 the company made an earning of -โ‚น21.16 Billion, an increase over its 2023 earnings that were of -โ‚น28.06 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) โ‚น12.04 B-156.93%
2024 -โ‚น21.16 Billion-24.59%
2023 -โ‚น28.06 Billion-67.84%
2022 -โ‚น87.24 Billion36.93%
2021 -โ‚น63.71 Billion-8.04%
2020 -โ‚น69.28 Billion-15.66%
2019 -โ‚น82.14 Billion12.23%
2018 -โ‚น73.19 Billion62.91%
2017 -โ‚น44.93 Billion17.78%
2016 -โ‚น38.15 Billion43.44%
2015 -โ‚น26.6 Billion60.69%
2014 -โ‚น16.55 Billion98.2%
2013 -โ‚น8.35 Billion
2011 -โ‚น4.93 Billion27.48%
2010 -โ‚น3.87 Billion-10.92%
2009 -โ‚น4.34 Billion95.77%
2008 -โ‚น2.22 Billion
2006 -โ‚น3.55 Billion-9.13%
2005 -โ‚น3.91 Billion34.74%
2004 -โ‚น2.9 Billion36.79%
2003 -โ‚น2.12 Billion

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-โ‚น6.75 Billion-157.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
โ‚น462.21 B 3,848.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-โ‚น22.66 Billion-293.52%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-โ‚น14.33 Billion-222.38%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-โ‚น4.27 Billion-136.39%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
โ‚น1.475 T 12,499.18%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
โ‚น817.53 B 6,883.12%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
โ‚น159.19 B 1,259.75%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel